Malignant neoplasm of ovary
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low-grade and high-grade ovarian serous carcinomas develop through independent pathways.
|
12644542 |
2003 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
|
12893203 |
2003 |
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found no evidence to suggest that BRAF is a low-risk LMP ovarian cancer susceptibility gene.
|
15904951 |
2005 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Germ line and somatic mutations of BRAF V599E in ovarian carcinoma.
|
17309670 |
2007 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have revealed frequent activating mutations of the gene for B-RAF, an effector of Ras protein in the mitogen-activated protein kinase pathway, in several malignancies, including melanoma, thyroid, colorectal and ovarian cancer.
|
17318013 |
2007 |
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, they suggest that the CI-1040-induced phenotypes depend on the mutational status of KRAS and BRAF in ovarian cancers.
|
19018267 |
2008 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We also identified two haplotypes in ERBB2 associated with an increased OC risk (P(global)=0.034) and a haplotype in BRAF that had a protective effect (P(global)=0.005).
|
19240718 |
2009 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E protein was expressed in BM of 42/76 (55.3%) melanomas, 1/15 (6.7%) ovarian cancers, 4/72 (5.5%) colorectal cancers, 1/355 (0.3%) lung cancers, 2/6 thyroid cancers and 1/2 choriocarcinomas.
|
22012135 |
2012 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Seven patients (30%) with PIK3CA mutations had coexisting MAPK pathway (KRAS, NRAS, BRAF) mutations (ovarian cancer, n = 5; endometrial cancer, n = 2), and two of these patients (ovarian cancer) achieved a response.
|
22271473 |
2012 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genetic analyses have identified BRAF V600E mutations in a subset of ovarian carcinomas.
|
22820660 |
2013 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The presence of the BRAF V600E mutation in SB/LGS ovarian cancer was associated with early stage disease and improved prognosis.
|
22930283 |
2013 |
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mutations of components of the mitogen-activated protein kinase pathway, mainly BRAF, are common in serous ovarian borderline tumors, whereas high-grade serous ovarian carcinomas rarely show this feature.
|
23089489 |
2013 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In a striking contrast to the sporadic cases, the expression of p53 was normal and KRAS/BRAF mutations absent in all LS-ovarian carcinomas.
|
23716351 |
2013 |
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
|
24889043 |
2014 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.
|
26490654 |
2015 |
Malignant neoplasm of ovary
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Mutations in BRAF and KRAS genes are the most frequent genetic aberrations found in low-grade serous ovarian carcinomas and serous and mucinous borderline tumors.
|
28992761 |
2017 |
Malignant neoplasm of ovary
|
0.600 |
Biomarker
|
disease |
BEFREE |
All these derivatives showed potent anti-ovarian cancer both in vitro and in vivo<i>.</i> The mechanism of anti-ovarian cancer was suggested to process via topoisomerase II and <sup>V600E</sup>BRAF inhibition.
|
31146483 |
2019 |